All news

Pic:getty/sohelparvezhaque

Pfizer acquires RSV therapeutic candidates

By Rachel Arthur

Pfizer will acquire ReViral, a privately-held clinical-stage company which is focused on novel antiviral therapeutics for respiratory syncytial virus (RSV), for up to $525m.

Pic:getty/maxiphoto

Catalent buys UK vaccine manufacturing centre

By Rachel Arthur

US company Catalent is acquiring the UK’s Vaccine Manufacturing and Innovation Centre in Harwell: a facility which had been planned to support COVID-19 and wider vaccine production and which is still under construction.

Pic:getty/jonathanknowles

Ocugen starts clinical trials for retinal gene therapy candidate

By Rachel Arthur

The first patient has been dosed in the Phase 1/2 clinical trial of OCU400, a modifier gene therapy candidate for the treatment of retinitis pigmentosa (RP) resulting from mutations in the nuclear receptor subfamily 2 group E member 3 (NR2E3) and Rhodopsin...

© GettyImages/Design Cells

Milestone approval for Kite CAR-T cell therapy

By Jane Byrne

The US FDA has approved Yescarta, Kite's CAR-T cell therapy, for initial treatment in adults with large B-cell lymphoma (LBCL) that is refractory to one prior therapy or that relapses within 12 months of first-line chemoimmunotherapy.

© GettyImages/John M Lund Photography Inc

Fujifilm to acquire Shenandoah Biotechnology

By Jane Byrne

Fujifilm Irvine Scientific, Inc, has announced the acquisition of Shenandoah Biotechnology, a company supplying recombinant proteins to the drug discovery, life science research, and cell and gene therapy markets.